Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy

Ju Han Song, Kyung Min Cho, Hyeoung Joon Kim, Yeo Kyeoung Kim, Nan Young Kim, Hee J E Kim, Tae Hyang Lee, Seung Yong Hwang, Tae Sung Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)-positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95% confidence interval (CI), 0.025-0.557; P=0.008] and overall survival (HR, 0.062; 95% CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients.

Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalOncology Reports
Volume34
Issue number1
DOIs
Publication statusPublished - 2015 Jul 1

Fingerprint

Nucleoside Transport Proteins
Cytarabine
Acute Myeloid Leukemia
Drug Therapy
Confidence Intervals
Nonparametric Statistics
Genes
Disease-Free Survival
Therapeutics
Multivariate Analysis
Gene Expression
Survival

Keywords

  • Acute myeloid leukemia
  • CNT3
  • Cytarabine
  • Prognosis
  • t(8;21) translocation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. / Song, Ju Han; Cho, Kyung Min; Kim, Hyeoung Joon; Kim, Yeo Kyeoung; Kim, Nan Young; Kim, Hee J E; Lee, Tae Hyang; Hwang, Seung Yong; Kim, Tae Sung.

In: Oncology Reports, Vol. 34, No. 1, 01.07.2015, p. 488-494.

Research output: Contribution to journalArticle

Song, Ju Han ; Cho, Kyung Min ; Kim, Hyeoung Joon ; Kim, Yeo Kyeoung ; Kim, Nan Young ; Kim, Hee J E ; Lee, Tae Hyang ; Hwang, Seung Yong ; Kim, Tae Sung. / Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. In: Oncology Reports. 2015 ; Vol. 34, No. 1. pp. 488-494.
@article{1e62e8c164db47ea9bc8dc2b0e665156,
title = "Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy",
abstract = "Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)-positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95{\%} confidence interval (CI), 0.025-0.557; P=0.008] and overall survival (HR, 0.062; 95{\%} CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients.",
keywords = "Acute myeloid leukemia, CNT3, Cytarabine, Prognosis, t(8;21) translocation",
author = "Song, {Ju Han} and Cho, {Kyung Min} and Kim, {Hyeoung Joon} and Kim, {Yeo Kyeoung} and Kim, {Nan Young} and Kim, {Hee J E} and Lee, {Tae Hyang} and Hwang, {Seung Yong} and Kim, {Tae Sung}",
year = "2015",
month = "7",
day = "1",
doi = "10.3892/or.2015.3959",
language = "English",
volume = "34",
pages = "488--494",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy

AU - Song, Ju Han

AU - Cho, Kyung Min

AU - Kim, Hyeoung Joon

AU - Kim, Yeo Kyeoung

AU - Kim, Nan Young

AU - Kim, Hee J E

AU - Lee, Tae Hyang

AU - Hwang, Seung Yong

AU - Kim, Tae Sung

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)-positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95% confidence interval (CI), 0.025-0.557; P=0.008] and overall survival (HR, 0.062; 95% CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients.

AB - Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)-positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95% confidence interval (CI), 0.025-0.557; P=0.008] and overall survival (HR, 0.062; 95% CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients.

KW - Acute myeloid leukemia

KW - CNT3

KW - Cytarabine

KW - Prognosis

KW - t(8;21) translocation

UR - http://www.scopus.com/inward/record.url?scp=84930020011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930020011&partnerID=8YFLogxK

U2 - 10.3892/or.2015.3959

DO - 10.3892/or.2015.3959

M3 - Article

C2 - 25955569

AN - SCOPUS:84930020011

VL - 34

SP - 488

EP - 494

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -